Chronic Heart Failure
Conditions
Brief summary
The Human leukocyte antigen G (HLA-G) is a non-classical, major histocompatibility complex class I (MHC-I) protein that modulates the immune response, inhibiting it in most cases. Physiologically expressed in the cells of some tissues, it increases in inflammatory reactions. Inflammation appears to play an important role in the development of chronic heart failure. This study aims to evaluate the levels of soluble HLA-G in patients with heart failure and to investigate the relationships between HLA-G and other clinical-functional parameters of the disease. Investigators hypothesize that the plasma levels of HLA-G could correlate with the clinical status of heart failure and could provide indications on patient's prognosis.
Interventions
DIAGNOSTIC_TESTplasmatic HLA-G
plasmatic HLA-G by blood sample
Sponsors
Piera Boschetto
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction \<40. * Clinical stability in the previous month prior to recruitment. * Absence of coexisting autoimmune diseases.
Exclusion criteria
* Subjects with over one year chronic heart failure diagnosis and in clinical stability for less than 1 month. * Presence of autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To measure plasma levels of soluble Human Leucocyte Antigen G (HLA-G) in patients with chronic heart failure (CHF) | Collection of whole blood at baseline, at 6 and 12 months from baseline | To measure the plasmatic levels of HLA-G in patients with stable chronic heart failure at baseline. To assess possible changes in HLA-G levels, due to CHF exacerbations, at 6 and 12 months from baseline |
| To measure the polymorphisms of Human Leucocyte Antigen G (HLA-G) gene | Collection of whole blood at baseline | To analyze the polymorphisms (Insertion/Deletion 14 pb and 3142 C\>G) of the HLA-G gene in patients with chronic heart failure (CHF) at baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To correlate the plasma levels of HLA-G with clinical-functional parameters of the chronic heart failure (CHF) in patients with CHF | At baseline and after 12 months | To correlate plasma levels of HLA-G with Brain Natriuretic Peptide (BNP) and left ventricle ejection fraction at baseline and at 12 months from baseline |
Countries
Italy
Outcome results
None listed